Month: November 2019

NEW YORK/BANGALORE (Reuters) – SoftBank Group Corp will this week launch a previously agreed tender offer for as much as $3 billion of WeWork shares, including up to $970 million owned by the office sharing company’s cofounder Adam Neumann, two people familiar with the matter said. The tender offer to the founders, investors and employees owning stock was expected to launch earlier this month but was delayed after SoftBank sought technical revisions to the offer documents, according to the sources. Last Thursday, Bloomberg reported that executives at SoftBank, the giant Japanese technology investment company, had been looking …read more […]

Is Himax Technologies, Inc. (NASDAQ:HIMX) a good equity to bet on right now? We like to check what the smart money thinks first before doing extensive research on a given stock. Although there have been several high profile failed hedge fund picks, the consensus picks among hedge fund investors have historically outperformed the market after […] …read more […]

The Medicines Company is developing a treatment for “bad” cholesterol. …read more […]

Stocks are volatile, but not actually risky Continue reading… …read more […]

These companies have a low financial burden Continue reading… …read more […]

It’s no secret that health care costs continue to rise, and new research from the Commonwealth Fund (TCF) indicates that Americans are paying more for their premiums and deductibles than ever before. …read more […]

One exec called the alliance “a complete game-changer for the industry.” …read more […]

Novartis AG is buying U.S. biotechnology company The Medicines Co for about $9.7 billion, the Swiss drugmaker said on Sunday, as it seeks to expand its portfolio of medicines against cardiovascular disease. Novartis is paying $85 per share in cash, an approximately 24% premium over The Medicines Co.’s closing share price of $68.55 on Nov. 22. New Jersey-based The Medicines Co’s top drug candidate is cholesterol-lowering drug inclisiran for heart patients, which could complement Novartis’s growing business with its heart-failure medicine Entresto, a slow-seller to start that has now crossed the $1 billion annual revenue threshold. …read more […]

Novartis AG is buying U.S. biotechnology company The Medicines Co for about $9.7 billion, the Swiss drugmaker said on Sunday, as it seeks to expand its portfolio of medicines against cardiovascular disease. Novartis is paying $85 per share in cash, an approximately 24% premium over The Medicines Co.’s closing share price of $68.55 on Nov. 22. New Jersey-based The Medicines Co’s top drug candidate is cholesterol-lowering drug inclisiran for heart patients, which could complement Novartis’s growing business with its heart-failure medicine Entresto, a slow-seller to start that has now crossed the $1 billion annual revenue threshold. …read more […]

The company is holding on to a record amount of liquid assets, which serves as a warning for investors Continue reading… …read more […]

Is Genesis Energy, L.P. (NYSE:GEL) a good bet right now? We like to analyze hedge fund sentiment before conducting days of in-depth research. We do so because hedge funds and other elite investors have numerous Ivy League graduates, expert network advisers, and supply chain tipsters working or consulting for them. There is not a shortage […] …read more […]

Novartis AG is buying U.S. biotechnology company The Medicines Co for about $9.7 billion, the Swiss drugmaker said on Sunday, as it seeks to expand its portfolio of medicines against cardiovascular disease. The deal is expected to help to broaden the Swiss drugmaker’s range of heart medicines and shore up growth threatened by patent expirations. Novartis is paying $85 per share in cash, an approximately 24% premium over The Medicines Co.’s closing share price of $68.55 on November 22, Novartis said in a statement, adding the transaction had been approved by the boards of directors of both …read more […]

Company beats on earnings, misses revenue forecasts Continue reading… …read more […]